Kamada Operating Expenses 2012-2024 | KMDA

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Revenue Gross Profit Operating Income EBITDA Net Income Shares Outstanding

Kamada operating expenses from 2012 to 2024. Operating expenses can be defined as the sum of all operating expenses for the given industry.

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Revenue Gross Profit Operating Income EBITDA Net Income Shares Outstanding

Kamada operating expenses from 2012 to 2024. Operating expenses can be defined as the sum of all operating expenses for the given industry.

Related Stocks
Company Name	Market Cap
Amgen (AMGN)	$172.8B
Vertex Pharmaceuticals (VRTX)	$125.8B
Regeneron Pharmaceuticals (REGN)	$111.1B
Bristol Myers Squibb (BMY)	$108.2B
Gilead Sciences (GILD)	$108B
CSL (CSLLY)	$97B
GSK (GSK)	$81.3B
Alnylam Pharmaceuticals (ALNY)	$38.6B
Argenex SE (ARGX)	$32.3B
BioNTech SE (BNTX)	$28B
Biogen (BIIB)	$27.5B
Illumina (ILMN)	$22.9B
Moderna (MRNA)	$22.1B
BeiGene (BGNE)	$21.6B
Genmab (GMAB)	$15B
BioMarin Pharmaceutical (BMRN)	$13.3B
Insmed (INSM)	$13.2B
Vaxcyte (PCVX)	$13.2B
Exact Sciences (EXAS)	$13B
Incyte (INCY)	$12.7B
Sarepta Therapeutics (SRPT)	$12B
Bio-Techne Corp (TECH)	$11.4B
QIAGEN (QGEN)	$9.9B
Bio-Rad Laboratories (BIO.B)	$9.3B
Roivant Sciences (ROIV)	$8.9B
Revolution Medicines (RVMD)	$8.4B
Exelixis (EXEL)	$8.4B
Intra-Cellular Therapies (ITCI)	$8B
Legend Biotech (LEGN)	$8B
Ascendis Pharma (ASND)	$7.9B